论文部分内容阅读
本期瑞士医学周报有两篇文章指出:在我们比较相信的和多年来对它的性质认识了的药物能发生迄今不熟悉的付作用。Knoblauch氏等描述了两个高血压病人在联合应用双肼苯哒嗪、利血平及DHCT治疗过程中发生了黄疸。临床症状、化验室检查,主要是肝脏活检说明是中毒性肝炎。药物的摄取与引起黄疸的原因之间的关系,可以通过两个病例中的一个再次服药试验肯定的,双肼苯哒嗪是负主要责任的药物。在下面的一篇文章中,Enat氏等报告了类似的联合应用双胼苯哒嗪和利血平(安哒血平)治疗一个高血压病人的观察,虽则这个例子的资料还不完整,然而这种观察可以被作为附加的证据,说明双肼哒嗪能够引起肝炎的相似症状,当然这种情况是罕见的。迄今为止只有个别的未见详细描述的病例,由双肼苯哒嗪诱发的肝损害、类似播散性红斑性狼疮样的综合症状群以及一例肉芽肿性肝病。
Two articles in this issue of the Swiss Medical Week state that the hitherto unfamiliar pay-off can occur with the drugs that we believe in and have been acquainted with for many years. Knoblauch et al. Described jaundice in the treatment of two hypertensive patients in combination with dizidzide, reserpine and DHCT. Clinical symptoms, laboratory tests, mainly liver biopsy indicate toxic hepatitis. The relationship between drug intake and the cause of jaundice can be tested again by taking one of two cases, with diazepam being the primary responsibility. In the following article, Enat et al. Reported similar observations regarding the combination of bispyridium and reserpine (diazepam) for a hypertensive patient, although the data in this case are incomplete. However, This observation can be used as additional evidence that bis-hydrazidazine can cause similar symptoms of hepatitis, of course, this situation is rare. To date, there have been only a few cases that were not described in detail, liver damage induced by hydralazine, a group of syndromes similar to disseminated lupus erythematosus, and one case of granulomatous liver disease.